Showing results (61-70 of 254) with videos related to

Sort By:
Pageof 26
The Journal of Antimicrobial Chemotherapy|August 28, 2015
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 cladesTomas Doyle, David T Dunn, Francesca Ceccherini-Silberstein, et al.
Plos One|January 12, 2018
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patientsAnnalisa Saracino, Alessandro Cozzi-Lepri, Milensu Shanyinde, et al.
Journal of Medical Virology|December 24, 2025
Development of a Next-Generation Sequencing Protocol for Assessing Lenacapavir Resistance in HIV-1 CapsidOmar El Khalili, Collins Ambe Chenwi, Daniele Spalletta, et al.
The Journal of Antimicrobial Chemotherapy|October 25, 2013
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapyGenny Meini, Barbara Rossetti, Claudia Bianco, et al.
Plos One|July 23, 2013
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophagesMatteo Surdo, Emanuela Balestra, Patrizia Saccomandi, et al.
Open Forum Infectious Diseases|January 15, 2021
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected PatientsVincenzo Malagnino, Carlotta Cerva, Antonella Cingolani, et al.
FEBS Letters|April 26, 2005
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugsJoeri Auwerx, Joke Van Nieuwenhove, Fátima Rodríguez-Barrios, et al.
Viruses|April 26, 2025
An In-Depth Characterization of SARS-CoV-2 Omicron Lineages and Clinical Presentation in Adult Population Distinguished by Immune StatusGreta Marchegiani, Luca Carioti, Luigi Coppola, et al.
Plos One|January 26, 2013
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesCharlotte Charpentier, Sidonie Lambert-Niclot, Claudia Alteri, et al.
HIV Medicine|January 22, 2021
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practiceDaniele Armenia, Yagai Bouba, Roberta Gagliardini, et al.
Pageof 26